William Blair Weighs in on Penumbra's Q1 Earnings (NYSE:PEN)

Penumbra, Inc. (NYSE:PEN - Free Report) - Research analysts at William Blair raised their Q1 2025 earnings per share estimates for Penumbra in a note issued to investors on Thursday, October 31st. William Blair analyst M. Kaczor now forecasts that the company will post earnings per share of $0.79 for the quarter, up from their prior estimate of $0.72. The consensus estimate for Penumbra's current full-year earnings is $2.58 per share. William Blair also issued estimates for Penumbra's Q2 2025 earnings at $1.00 EPS.

PEN has been the subject of several other reports. Citigroup raised their target price on shares of Penumbra from $178.00 to $200.00 and gave the company a "neutral" rating in a research note on Thursday, August 22nd. Leerink Partnrs upgraded shares of Penumbra to a "strong-buy" rating in a research note on Tuesday, September 3rd. Royal Bank of Canada raised their target price on shares of Penumbra from $205.00 to $222.00 and gave the company an "outperform" rating in a research note on Tuesday, October 8th. Needham & Company LLC reissued a "hold" rating on shares of Penumbra in a research report on Thursday. Finally, Truist Financial raised their price objective on Penumbra from $200.00 to $235.00 and gave the company a "buy" rating in a research report on Monday, October 14th. Five investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Penumbra has an average rating of "Moderate Buy" and a consensus price target of $226.67.

Penumbra Stock Down 1.6 %

Shares of NYSE:PEN traded down $3.79 during trading on Monday, hitting $229.51. 453,729 shares of the company were exchanged, compared to its average volume of 384,682. Penumbra has a fifty-two week low of $148.00 and a fifty-two week high of $277.34. The stock has a market cap of $8.81 billion, a price-to-earnings ratio of 266.87, a P/E/G ratio of 2.62 and a beta of 0.51. The company has a current ratio of 5.82, a quick ratio of 3.77 and a debt-to-equity ratio of 0.02. The firm has a fifty day moving average price of $201.36 and a two-hundred day moving average price of $193.93.

Penumbra (NYSE:PEN - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $0.85 EPS for the quarter, topping analysts' consensus estimates of $0.69 by $0.16. Penumbra had a net margin of 2.97% and a return on equity of 8.99%. The company had revenue of $301.04 million during the quarter, compared to the consensus estimate of $297.36 million. During the same period in the prior year, the business posted $0.67 EPS. The company's quarterly revenue was up 11.1% on a year-over-year basis.

Penumbra declared that its Board of Directors has approved a share buyback plan on Tuesday, August 13th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to purchase up to 2.6% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's board believes its shares are undervalued.

Insider Buying and Selling at Penumbra

In other news, CEO Adam Elsesser sold 1,620 shares of the stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $200.00, for a total transaction of $324,000.00. Following the sale, the chief executive officer now directly owns 925,962 shares of the company's stock, valued at approximately $185,192,400. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Penumbra news, Director Harpreet Grewal sold 782 shares of the business's stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $204.11, for a total transaction of $159,614.02. Following the completion of the transaction, the director now directly owns 8,863 shares in the company, valued at $1,809,026.93. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Adam Elsesser sold 1,620 shares of the firm's stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $200.00, for a total value of $324,000.00. Following the completion of the sale, the chief executive officer now directly owns 925,962 shares in the company, valued at approximately $185,192,400. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 34,368 shares of company stock valued at $6,893,118 in the last three months. Corporate insiders own 5.00% of the company's stock.

Institutional Trading of Penumbra

Several institutional investors and hedge funds have recently modified their holdings of PEN. GAMMA Investing LLC raised its stake in Penumbra by 111.1% during the third quarter. GAMMA Investing LLC now owns 171 shares of the company's stock worth $33,000 after acquiring an additional 90 shares in the last quarter. WASHINGTON TRUST Co acquired a new position in Penumbra during the 2nd quarter worth approximately $54,000. Park Place Capital Corp increased its position in Penumbra by 1,473.9% during the 3rd quarter. Park Place Capital Corp now owns 362 shares of the company's stock worth $70,000 after purchasing an additional 339 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in Penumbra by 1,845.0% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 389 shares of the company's stock valued at $70,000 after purchasing an additional 369 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new stake in Penumbra in the first quarter valued at approximately $89,000. 88.88% of the stock is currently owned by institutional investors.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.